Delving into the Latest Updates on ZGGS18 with Synapse

Overview

Basic Info

Drug Type

Antibody fusion proteins

Synonyms

ZGGS 18, ZGGS-18

Target

TGF-β x VEGF

Mechanism

TGF-β inhibitors(Transforming growth factor beta inhibitors), VEGF inhibitors(Vascular endothelial growth factor inhibitors)

Therapeutic Areas

Neoplasms

Active Indication

Advanced Malignant Solid NeoplasmSolid tumor

Inactive Indication-

Originator Organization

Suzhou Zelgen Biopharmaceuticals Co., Ltd.

Active Organization

Suzhou Zelgen Biopharmaceuticals Co., Ltd.

Inactive Organization-

Drug Highest PhasePhase 1/2

First Approval Date-

Regulation-

Login to view timeline

主要目的：（1）探索ZGGS18的耐受性和安全性；（2）探索ZGGS18的最大耐受剂量（MTD），确定II期推荐剂量（RP2D）/后续推荐剂量。次要目的：（1）评价ZGGS18的人体药代动力学特征；（2）探索ZGGS18的有效性；（3）评价ZGGS18的免疫原性。

[Translation]

Primary objectives: (1) To explore the tolerability and safety of ZGGS18; (2) To explore the maximum tolerated dose (MTD) of ZGGS18 and determine the recommended dose for Phase II (RP2D)/subsequent recommended dose. Secondary objectives: (1) To evaluate the pharmacokinetic characteristics of ZGGS18 in humans; (2) To explore the efficacy of ZGGS18; (3) To evaluate the immunogenicity of ZGGS18.

Start Date09 Nov 2022

Sponsor / Collaborator

Suzhou Zelgen Biopharmaceuticals Co., Ltd.

100 Clinical Results associated with ZGGS18

Login to view more data

100 Translational Medicine associated with ZGGS18

Login to view more data

100 Patents (Medical) associated with ZGGS18

Login to view more data

100 Deals associated with ZGGS18

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Advanced Malignant Solid Neoplasm	Phase 2	CN	Suzhou Zelgen Biopharmaceuticals Co., Ltd.	09 Nov 2022
Solid tumor	Phase 1	US	Suzhou Zelgen Biopharmaceuticals Co., Ltd.	26 Jul 2022

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05584800 (ASCO2024) Manual	Phase 1	Advanced Malignant Solid Neoplasm	21	ZGGS18	adkoxsqucv(cyyhwmvhet) = wvajexrwsw dvjhqapeap (estrycoznp ) View more	Positive	24 May 2024